COMP <GO>
MRK vs LLY // 10Y YIELD & FRED MACRO BETA
Merck & Company Inc. Common Stock (new) (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MRK 6
— LLY 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: MRK
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRK VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRK | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.80% | 83.64% | -8.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.70% | 32.36% | -11.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.3x | 36.4x | -21.12 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.42% | 2.30% | +1.12 | MRK | /fcf-yield <GO> |
| Operating Margin | 34.30% | 40.21% | -5.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 28.10% | 31.90% | -3.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 1.30% | 45.51% | -44.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.26% | 0.49% | +1.77 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.19 | 9.29 | -4.10 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 77.9 | -21.02 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.92 | 0.51 | +0.41 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 26.3x | -7.85 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $361.02B | $1.33T | -$973.39B | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRK REV | LLY REV | MRK GROSS % | LLY GROSS % | MRK FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.01B | $65.18B | 74.8% | 83.0% | $12.36B | $16.81B |
| FY 2024 | $64.17B | $45.04B | 76.3% | 81.3% | $18.10B | $8.82B |
| FY 2023 | $60.12B | $34.12B | 44.0% | 79.3% | $10.30B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRK // BETA 0.92
LLY // BETA 0.51